{"id":"W4380078993","doi":"10.1002/hon.3163_80","title":"SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Calvary Mater Newcastle; National Institutes of Health; Masarykova Univerzita; Barts Health NHS Trust; BeiGene; Institut Bergonié; Tianjin Medical University; Peking University; Università degli Studi dell'Insubria; Jewish General Hospital; Harbin Medical University","keywords":"Medicine; Rituximab; Follicular lymphoma; Ibrutinib; Internal medicine; Hazard ratio; Ofatumumab; Randomized controlled trial; Clinical endpoint; Lymphoma; Placebo; Randomization; International Prognostic Index; Surgery; Oncology; Gastroenterology; Confidence interval; Leukemia; Chronic lymphocytic leukemia; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002207003,0.001357733,0.002697152,0.0004438264,0.0003006089,0.0009238859,0.0008131814,0.001253929,0.005151811],"category_scores_gemma":[0.001748908,0.0006968918,0.001728211,0.0004047681,0.001105622,0.0008292968,0.0005002581,0.002087795,0.0008193167],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008619209,"about_ca_system_score_gemma":0.001100597,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001080722,"about_ca_topic_score_gemma":0.002866487,"domain_scores_codex":[0.9989461,0.0006692323,0.00007135938,0.0001442221,0.00007315173,0.00009593082],"domain_scores_gemma":[0.9992437,0.0001831958,0.0002187066,0.00006762522,0.00005726643,0.0002294144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9898516,0.001361518,0.0004104947,0.0002901721,0.0006999809,0.0000180703,0.00002099086,0.0001742191,0.001240205,0.00008227612,0.0004410324,0.005409572],"study_design_scores_gemma":[0.9643685,0.03281624,0.001289479,0.00002857466,0.0004113449,0.00001854858,0.00001164675,0.0002697253,0.0001094938,0.0001324994,0.0005357622,0.000008349935],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842811,0.005905418,0.0005705647,0.000845539,0.0008185942,0.003568442,0.00104628,0.0001257434,0.002838289],"genre_scores_gemma":[0.9852363,0.002515133,0.001488286,0.001493877,0.0006109882,0.00361382,0.001261895,0.00002683097,0.003752826],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005151811,"threshold_uncertainty_score":0.0172345,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0345031175598008,"score_gpt":0.3562166182791113,"score_spread":0.3217135007193105,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}